flexprd, Author at IVI - Page 26 of 34

IVI’s Mark Linthicum in Morning Consult: Why Understanding Value is Central to True Health Care Reform

Mark Linthicum makes the case that value-based spending should be the focus of health care reform efforts in Washington, D.C. On September 13th health care stakeholders came together at the National Press Club to discuss better approaches to measuring value. Read Full Article Here

IVI-Sponsored Health Affairs Policymaker Forum Assembles Key Stakeholders

On September 13th, the Innovation and Value Initiative was proud to sponsor a special Health Affairs briefing in Washington, D.C. Over 200 of the country’s most influential health care stakeholders and public policy thought leaders gathered to address the topic of value in health care. Focusing on “Understanding the Value of Innovations in Medicine,” this […]

Sachs Provides an Overview of FDA User Fee Reauthorization Bill

In a recent post on the IVI-Sponsored Health Affairs blog series, Rachel Sachs provides an overview of the House of Representative’s latest draft of the FDA user fee authorization bill. Sachs also examines changes in the bill from the earlier Senate markup, including incorporation of provisions from the bipartisan RACE Act and provides a possible […]

IVI’s Lakdawalla and Balch Participate in NPAF Consortium

On May 17th, IVI’s Executive Director, Darius Lakdawalla, and Panel of Health Advisors member, Alan Blach, spoke at the National Patient Advocate Foundation’s (NPAF) Spring 2017 Policy Consortium. The event launched the NPAF “Roadmap to Clarity in Healthcare Decision-Making.” Both NPAF and IVI are committed to providing patients with accessible and useful information about the […]

Discussing the Challenges of Value-Based Pricing in STAT News

In a new commentary for STAT News, Anupam Jena (part of IVI’s scientific advisory group) and Dana Goldman discuss the advantages of value-based pricing, pointing out several of the key challenges that complicate the application of health technology assessments. Jena and Goldman make the case that more transparency is needed and that an open-source model […]

IVI’s Lakdawalla in WSJ: Look to Major League Baseball for Drug Pricing Insight

In a new commentary appearing in The Wall Street Journal, Dana Goldman and IVI Executive Director, Darius Lakdawalla, turn to the national pastime to provide a fresh perspective on the issue of drug pricing and the return on investment pharmaceutical companies need to sustain innovation. In baseball, the salaries are high and the talent pool is […]